On this page
Source-checked 7 October 2026: Australia’s TGA has updated warnings for GLP-1 receptor agonists and the dual GIP/GLP-1 medicine tirzepatide across several distinct issues: aspiration around general anaesthesia or deep sedation, potential suicidal thoughts, a Mounjaro oral-contraception interaction warning, and the rare eye disorder NAION. A warning is a risk-communication action—not proof that every reported event was caused by a medicine.
Seek urgent medical assessment for sudden loss of vision or rapidly worsening eyesight. Before a procedure involving general anaesthesia or deep sedation, tell the treating team about all medicines being used. This page cannot assess an individual symptom or risk.
Australia’s GLP-1 warning updates at a glance
| Update | TGA position | How to read it |
|---|---|---|
| Aspiration during anaesthesia or deep sedation | Product information updated in 2025 | Delayed gastric emptying may leave residual stomach contents; procedure teams need an accurate medicine history. |
| Suicidal thoughts or behaviours | Class warnings harmonised in December 2025 | TGA said evidence was insufficient to establish a causal association, but aligned precautionary wording. |
| Mounjaro and oral contraception | Warning updated | An association with reduced effectiveness could not be ruled out; follow current Product Information and professional advice. |
| NAION eye disorder | Class-wide Product Information updates announced 23 July 2026 | TGA described a potential rare but severe risk. Evidence was stronger for semaglutide than for dulaglutide or tirzepatide. |
| Counterfeit or unapproved products | Separate regulatory concern | Quality and authenticity risks are different from known adverse effects of registered medicines. |
1. Aspiration risk around procedures
GLP-1 medicines can delay gastric emptying. The TGA updated Australian Product Information to warn about pulmonary aspiration in people receiving general anaesthesia or deep sedation. The practical point is communication: procedure and anaesthesia teams need to know which medicines a person uses so they can assess risk under current clinical guidance.
This guide does not tell anyone to stop, skip or alter a medicine. Peri-procedural decisions are individual medical decisions.
2. Suicidal-thought warning: signal is not causality
After reviewing post-market reports and other evidence, the TGA’s expert committee found insufficient evidence to establish a causal association between GLP-1 medicines and suicidal or self-harming thoughts or behaviours. The regulator nevertheless harmonised warnings across the class so clinicians and consumers receive consistent precautionary information.
Counts in the Database of Adverse Event Notifications are reports, not confirmed caused events. Reporting systems are designed to detect signals; they cannot by themselves establish incidence or causality.
3. Mounjaro and oral contraception
The TGA said an association between Mounjaro use and reduced oral-contraceptive effectiveness could not be ruled out, and product warnings were updated. Readers should use the current Australian Product Information and seek advice from an appropriate health professional rather than relying on overseas labels or social-media summaries.
4. NAION and sudden vision loss
On 23 July 2026 the TGA announced Product Information updates concerning non-arteritic anterior ischaemic optic neuropathy (NAION), a rare disorder that can cause severe vision loss. The regulator said available evidence may support an association for semaglutide, while evidence did not support the same association for dulaglutide or tirzepatide at that time. Precautionary post-market wording was applied across the class.
That nuance matters: a class-wide label update does not mean identical evidence or identical measured risk for every product.
For the product-specific evidence, report-count limitations and the difference between tirzepatide and semaglutide conclusions, read our Mounjaro and NAION evidence guide.
How to interpret a medicine-safety update
| Term | Meaning | What it does not prove |
|---|---|---|
| Adverse-event report | A suspected event submitted after medicine use | That the medicine caused it |
| Safety signal | Information warranting further assessment | The size or certainty of a risk |
| Product Information warning | Regulator-approved risk communication | That every user will experience the event |
| Causal association | Evidence supports cause and effect | That individual risk is the same for everyone |
Which Australian products are covered?
The TGA’s class communications discuss marketed GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide, including Ozempic, Wegovy, Saxenda, Trulicity and Mounjaro. Indications and evidence differ by product. Use our Australian GLP-1 status hub for the brand comparison, and the Mounjaro PBS guide for reimbursement status.
Counterfeits are a separate safety problem
A counterfeit, falsified or unapproved product may have the wrong ingredient, strength, sterility or labelling. That risk cannot be estimated from the Product Information of a registered medicine. Check our TGA counterfeit-safety alert explainer for the evidence framework.
Frequently asked questions
Did the TGA prove GLP-1 medicines cause suicidal thoughts?
No. The TGA said the evidence was insufficient to establish causality, while still harmonising precautionary warnings.
Is NAION proven for every GLP-1 medicine?
No. The July 2026 update described differing evidence across products, with a possible association for semaglutide and insufficient support for dulaglutide or tirzepatide at that time.
Should a medicine be stopped before surgery?
This page cannot make that decision. Tell the procedural team about all medicines and follow current, individual clinical instructions.
Do adverse-event numbers show how common a side effect is?
Not reliably. Spontaneous reports lack a complete denominator and may be affected by reporting patterns.
Where is the most current Australian warning?
Use the latest TGA-approved Product Information and dated TGA safety update.
Primary Australian sources
- TGA: Product warnings updated for GLP-1 receptor agonists — 1 December 2025.
- TGA: GLP-1 medicines and NAION risk — 23 July 2026.
- TGA: pulmonary aspiration warning — 2025.
Editorial status: Knowledge-only. Primary-source claims checked 7 October 2026. No treatment or dosing advice is provided.
How to cite this article
GLP-1 Safety Warnings Australia (2026): TGA Updates Explained. Elite Peps Australia. Published 7 October 2026; updated 8 October 2026. https://elitepepsaustralia.com/glp-1-safety-warnings-australia-2026-tga-updates-explained/
Source checks: Consult the primary studies, trial records and regulator documents linked in this article for current evidence and status. Publication and update dates do not by themselves indicate an evidence review.